



## Clinical trial results:

### A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance

#### Summary

EudraCT number	2017-001121-40
Trial protocol	GB DE FR
Global end of trial date	05 May 2020

#### Results information

Result version number	v1 (current)
This version publication date	21 May 2021
First version publication date	21 May 2021

#### Trial information

##### Trial identification

Sponsor protocol code	PEA Bridging Study
-----------------------	--------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03273257
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	International CTEPH Association (ICA)
Sponsor organisation address	c/o artax Fide Consult AG, Gartenstrasse 95, Basel, Switzerland,
Public contact	Gérald Simonneau, International CTEPH Association (ICA), info@cteph-association.org
Scientific contact	David Jenkins, International CTEPH Association (ICA), 041 413797970, info@cteph-association.org

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 May 2020
Global end of trial reached?	Yes
Global end of trial date	05 May 2020
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to assess the efficacy of riociguat on preoperative PVR in patients with operable CTEPH.

Protection of trial subjects:

Patients were treated at expert centres with many years of experience in the management of CTEPH, and all patients were to receive the recommended gold standard treatment for operable CTEPH, i.e. PEA surgery. As per the protocol, surgery was to be performed by the principal surgeon of the site. Moreover, an unblinded, independent data safety monitoring board periodically reviewed safety data.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 7
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	France: 1
Worldwide total number of subjects	14
EEA total number of subjects	14

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6
From 65 to 84 years	8

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Eligible patients were recruited at 3 expert centres for CTEPH in France, Germany and the UK between August 2018 and May 2020.

### Pre-assignment

Screening details:

Patients could undergo a screening period of up to 90 days prior to the baseline visit in order to assess eligibility of patients and to allow for the washout of prohibited medications. A total of 17 patients were screened; of those, 14 were enrolled into the study.

### Period 1

Period 1 title	Randomisation (no drug treatment yet)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment arm

Arm description:

Patients were randomised to receive riociguat for 90 days prior to surgery

Arm type	Active comparator
Investigational medicinal product name	Riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Patients were randomised to receive placebo for 90 days prior to surgery

Arm type	Placebo
Investigational medicinal product name	Matching placebo to riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo was given tid, mimicking the dosing scheme for riociguat

Number of subjects in period 1	Treatment arm	Placebo
Started	7	7
Completed	7	7

## Period 2

Period 2 title	Treatment period
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment arm

Arm description:

Patients received riociguat for 90 days prior to surgery.

Arm type	Active comparator
Investigational medicinal product name	Riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Patients received placebo for 90 days prior to surgery.

Arm type	Placebo
Investigational medicinal product name	Matching placebo to riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo was given tid, mimicking the dosing scheme for riociguat

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: One patient died after randomisation, but before starting study treatment. As per the SAP, baseline characteristics are reported for the ITT population, which is defined as patients having received at least one dose of IMP. Therefore, the patient who died before starting treatment was not included in the analysis of baseline characteristics, and a new period had to be defined to account for this.

<b>Number of subjects in period 2<sup>[2]</sup>[3]</b>	Treatment arm	Placebo
Started	7	6
Completed	6	5
Not completed	1	1
Inability to schedule PEA according to protocol	1	1

**Notes:**

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One patient died after randomisation, but before starting study treatment. As per the SAP, baseline characteristics are reported for the ITT population, which is defined as patients having received at least one dose of IMP. Therefore, the patient who died before starting treatment was not included in the analysis of baseline characteristics; however, he is considered to have enrolled in the trial.

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: One patient in the placebo arm died after randomisation, but before starting study treatment.

**Period 3**

Period 3 title	PEA (no more drug treatment)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment arm

**Arm description:**

Patients had received riociguat for 90 days prior to surgery and underwent PEA surgery during this period

Arm type	Active comparator
Investigational medicinal product name	Riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

<b>Arm title</b>	Placebo
------------------	---------

**Arm description:**

Patients had received placebo for 90 days prior to surgery and underwent PEA surgery during this period

Arm type	Placebo
Investigational medicinal product name	Matching placebo to riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

---

**Dosage and administration details:**

Placebo was given tid, mimicking the dosing scheme for riociguat

<b>Number of subjects in period 3</b>	Treatment arm	Placebo
Started	6	5
Completed	6	5

---

**Period 4**

Period 4 title	Post-surgery observation
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment arm

## Arm description:

Patients had received riociguat for 90 days prior to surgery and had undergone PEA surgery

Arm type	Active comparator
Investigational medicinal product name	Riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.

Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.

<b>Arm title</b>	Placebo
------------------	---------

## Arm description:

Patients had received placebo for 90 days prior to surgery and had undergone PEA surgery

Arm type	Placebo
----------	---------

Investigational medicinal product name	Matching placebo to riociguat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo was given tid, mimicking the dosing scheme for riociguat

<b>Number of subjects in period 4</b>	Treatment arm	Placebo
Started	6	5
Completed	3	3
Not completed	3	2
Study terminated	3	2



## Baseline characteristics

### Reporting groups

Reporting group title	Treatment arm
Reporting group description: Patients received riociguat for 90 days prior to surgery.	
Reporting group title	Placebo
Reporting group description: Patients received placebo for 90 days prior to surgery.	

Reporting group values	Treatment arm	Placebo	Total
Number of subjects	7	6	13
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
median	66	67	-
full range (min-max)	48 to 75	52 to 74	-
Gender categorical Units: Subjects			
Female	4	1	5
Male	3	5	8
Race Units: Subjects			
White	6	6	12
Black African	1	0	1
Received beta blockers between enrolment and PEA Units: Subjects			
Yes	3	0	3
No	4	6	10
Received vitamin K antagonists between enrolment and PEA Units: Subjects			
Yes	1	2	3
No	6	4	10
Received new/direct oral anticoagulants between enrolment and PEA Units: Subjects			

Yes	6	4	10
No	1	2	3

Body mass index Units: kg/m <sup>2</sup> arithmetic mean standard deviation	31.2 ± 3.9	25.4 ± 1.7	-
PVR at diagnosis Units: dyn*sec/cm <sup>5</sup> arithmetic mean standard deviation	944.0 ± 92.7	1007.5 ± 368.2	-
mPAP at diagnosis Units: mmHg arithmetic mean standard deviation	50.3 ± 8.4	53.2 ± 4.8	-

## End points

### End points reporting groups

Reporting group title	Treatment arm
Reporting group description: Patients were randomised to receive riociguat for 90 days prior to surgery	
Reporting group title	Placebo
Reporting group description: Patients were randomised to receive placebo for 90 days prior to surgery	
Reporting group title	Treatment arm
Reporting group description: Patients received riociguat for 90 days prior to surgery.	
Reporting group title	Placebo
Reporting group description: Patients received placebo for 90 days prior to surgery.	
Reporting group title	Treatment arm
Reporting group description: Patients had received riociguat for 90 days prior to surgery and underwent PEA surgery during this period	
Reporting group title	Placebo
Reporting group description: Patients had received placebo for 90 days prior to surgery and underwent PEA surgery during this period	
Reporting group title	Treatment arm
Reporting group description: Patients had received riociguat for 90 days prior to surgery and had undergone PEA surgery	
Reporting group title	Placebo
Reporting group description: Patients had received placebo for 90 days prior to surgery and had undergone PEA surgery	

### Primary: Change in PVR from baseline to immediately before PEA

End point title	Change in PVR from baseline to immediately before PEA
End point description:	
End point type	Primary
End point timeframe: 90 days	

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6 <sup>[1]</sup>	5 <sup>[2]</sup>		
Units: percent change from baseline				
arithmetic mean (standard deviation)	-28.4 (± 16.2)	-6.9 (± 27.9)		

Notes:

[1] - One subject was discontinued during the treatment phase

[2] - One subject was discontinued during the treatment phase

### Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis of primary endpoint
Comparison groups	Treatment arm v Placebo
Number of subjects included in analysis	11
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.139
Method	2-sample Wilcoxon rank sum test

### Secondary: Change in PVR from baseline to 6 months post-PEA

End point title	Change in PVR from baseline to 6 months post-PEA
End point description:	
End point type	Secondary
End point timeframe:	
270 days	

<b>End point values</b>	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 <sup>[3]</sup>	3 <sup>[4]</sup>		
Units: percent change from baseline				
arithmetic mean (standard deviation)	-68.1 (± 9.8)	-83.0 (± 2.2)		

Notes:

[3] - One subject was discontinued during the treatment phase and 3 during post-surgery follow-up

[4] - One subject was discontinued during the treatment phase and 2 during post-surgery follow-up

### Statistical analyses

No statistical analyses for this end point

### Secondary: All-cause death, PH-related hospitalisation, need for PAH-targeted therapy or WHO functional class unchanged or worse between randomisation and 6 months post-PEA (composite endpoint)

End point title	All-cause death, PH-related hospitalisation, need for PAH-targeted therapy or WHO functional class unchanged or worse between randomisation and 6 months post-PEA (composite endpoint)
End point description:	
End point type	Secondary

End point timeframe:

270 days

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
Experienced endpoint event	6	5		
Did not experience endpoint event	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Intraoperative circulatory arrest time

End point title      Intraoperative circulatory arrest time

End point description:

End point type      Secondary

End point timeframe:

intraoperative

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: minutes				
arithmetic mean (standard deviation)	32 (± 9)	40 (± 12)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Intraoperative surgery-related complications

End point title      Intraoperative surgery-related complications

End point description:

The occurrence of any of the following complications will be assessed:

- Bleeding and/or blood loss >1 L in 12 hours
- Airway bleed with need for extracorporeal membrane oxygenation
- Any use of extracorporeal membrane oxygenation for respiratory or haemodynamic support, specified as venovenous or veno-arterial
- Prolonged ventilation >96 hours
- Need for tracheostomy

- Need for drainage of pericardial effusion
- Neurological complications, ie, stroke, cerebral, subdural bleeding
- Reintubation or noninvasive ventilation for reperfusion response
- Haemoptysis requiring any intervention
- Renal failure requiring dialysis
- Wound infections
- Pneumonia
- Prolonged need for inotropic support ( $\geq 5$  days)

End point type	Secondary
End point timeframe:	
intraoperative	

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
Experienced endpoint event	0	0		
Did not experience endpoint event	6	5		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Surgical evaluation of specimen: ease of dissection plane

End point title	Surgical evaluation of specimen: ease of dissection plane
End point description:	

End point type	Secondary
End point timeframe:	
intraoperative	

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
Easier than normal	1	1		
Normal	3	4		
More difficult than normal	2	0		

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Surgical evaluation of specimen: completeness of disease clearance**

---

End point title	Surgical evaluation of specimen: completeness of disease clearance
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:  
intraoperative

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
Better than expected	0	0		
As expected	6	5		
Worse than expected	0	0		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Surgical evaluation of specimen: appearance of clot**

---

End point title	Surgical evaluation of specimen: appearance of clot
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:  
intraoperative

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
More solid than usual	0	0		
Normal	4	5		
More friable than usual	2	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Surgical evaluation of specimen: appearance of vessel wall

End point title      Surgical evaluation of specimen: appearance of vessel wall

End point description:

End point type      Secondary

End point timeframe:

intraoperative

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
More solid than usual	0	0		
Normal	4	5		
More friable than usual	2	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: All-cause death

End point title      All-cause death

End point description:

End point type      Secondary

End point timeframe:

270 days

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	5		
Units: Number of patients				
Died	0	0		
Did not die	6	5		

## Statistical analyses



No statistical analyses for this end point

---

**Secondary: Withdrawal during randomised treatment phase**

---

End point title	Withdrawal during randomised treatment phase
-----------------	--

End point description:

Only withdrawals after randomisation but before PEA are included

End point type	Secondary
----------------	-----------

End point timeframe:

90 days

---

End point values	Treatment arm	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	6		
Units: Number of patients				
Withdrew	1	1		
Did not withdraw	6	5		

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From informed consent until study completion (270-360 days) or early termination

Adverse event reporting additional description:

Events reported are treatment-emergent adverse events, i.e. any event not present before exposure to study drug or any event already present that worsened in either intensity or frequency after exposure to study drug, in patients who actually received any study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	Treatment arm
-----------------------	---------------

Reporting group description:

Patients received riociguat for 90 days prior to surgery, then underwent PEA surgery and were subsequently followed up for 6 months

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Patients received placebo for 90 days prior to surgery, then underwent PEA surgery and were subsequently followed up for 6 months

Serious adverse events	Treatment arm	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 7 (14.29%)	2 / 6 (33.33%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Gastrointestinal disorders			
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary hypertension	Additional description: Worsening symptoms of CTEPH, including increased NT-proBNP, peripheral oedema and breathlessness		
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Mediastinitis			

subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Treatment arm	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	5 / 6 (83.33%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Hypotension			
subjects affected / exposed	3 / 7 (42.86%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Surgical and medical procedures			
Drug therapy			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Discomfort			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	2 / 7 (28.57%)	3 / 6 (50.00%)	
occurrences (all)	2	4	
Feeling cold			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	

Oedema peripheral subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 6 (16.67%) 1	
Pyrexia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Reproductive system and breast disorders Menorrhagia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	2 / 6 (33.33%) 2	
Dyspnoea subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 2	2 / 6 (33.33%) 4	
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Epistaxis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Hypoxia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 6 (16.67%) 1	
Productive cough subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	

Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Anxiety disorder subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Confusional state subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Delirium subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Restlessness subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Sleep disorder subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 6 (0.00%) 0	
Investigations			
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Inflammatory marker increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Weight increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Procedural haemorrhage			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Vaccination complication			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Bradycardia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Cardiac failure			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Palpitations			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Tachyarrhythmia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Headache			
subjects affected / exposed	3 / 7 (42.86%)	2 / 6 (33.33%)	
occurrences (all)	4	2	
Lethargy			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Memory impairment			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Paraesthesia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 6 (16.67%) 1	
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 6 (16.67%) 4	
Eye disorders Retinal artery occlusion subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	2 / 6 (33.33%) 2	
Abdominal pain upper subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	0 / 6 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	4 / 7 (57.14%) 4	0 / 6 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 6 (0.00%) 0	
Dyspepsia subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 4	0 / 6 (0.00%) 0	
Eructation subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0	
Flatulence			

subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Nausea			
subjects affected / exposed	3 / 7 (42.86%)	0 / 6 (0.00%)	
occurrences (all)	5	0	
Toothache			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Back pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Chest wall haematoma			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Joint swelling			
subjects affected / exposed	0 / 7 (0.00%)	3 / 6 (50.00%)	
occurrences (all)	0	4	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Pain in extremity			



subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1	
Infections and infestations Lower respiratory tract infection subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Pneumonia subjects affected / exposed occurrences (all)  Post procedural infection subjects affected / exposed occurrences (all)  Urinary tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0  0 / 7 (0.00%) 0  1 / 7 (14.29%) 1  1 / 7 (14.29%) 1  3 / 7 (42.86%) 3	1 / 6 (16.67%) 1  1 / 6 (16.67%) 1  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)  Dyslipidaemia subjects affected / exposed occurrences (all)  Hyperglycaemia subjects affected / exposed occurrences (all)  Hyperkalaemia subjects affected / exposed occurrences (all)  Hypokalaemia subjects affected / exposed occurrences (all)  Hypomagnesaemia	1 / 7 (14.29%) 1  1 / 7 (14.29%) 1  1 / 7 (14.29%) 1  1 / 7 (14.29%) 1  3 / 7 (42.86%) 3	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0	

subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	
occurrences (all)	2	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated after enrolling only 14 out of 88 planned patients due to slow recruitment and further limitations imposed by the COVID-19 pandemic. No firm conclusions can be drawn based on the study data due to the limited sample size.
--

Notes: